As the presence of tumor hypoxia may confer resistance to EGFR inhibitors, we performed growth inhibition experiments under normoxic and hypoxic conditions for the tyrosine kinase inhibitor erlotinib and the monoclonal antibody cetuximab on three human, cetuximab sensitive HNSCC cell lines. Here, EGFR is linked to neoplasm.